Clinical stage biopharmaceutical firm Agentix Corp (OTCMKTS:AGTX) has had a pretty tough time in the markets over the course of the past week and during that period, the company’s stock has tanked by as much as 11%.
Trading Data
On Tuesday, AGTX stock ended flat at $0.50 with more than 4.5k shares traded, compared to its average volume of 420 shares. The stock has moved within a range of $0.5000 – 0.5000 after opening trading at $0.50.
Discusses 2022 Clinical Development Efforts and Potential Uplisting with The Stock Day Podcast
That being said, it should also be noted that yesterday, the company was in focus after its Chief Executive Officer Rudy Mazzochi went to The Stock Day Podcast and engaged in a chat with the podcast host Everett Jolly. It is a highly popular podcast and can provide a company with a major platform through which it can talk about its business.
The company is currently engaged in coming up with innovative therapeutics for treating metabolic diseases. At the beginning of the chat, the thrust of the discussion was centred around the background of AGENTIX as a firm and the moved on to the current projects in which the company was involved.
Mazzochi noted during the chat that AGENTIX decided to shift its focus to only pharmaceutical applications of its technology. That was an important revelation from the CEO of the company and it remains to be seen how the market reacts to that news in the coming days.
Technical Data
AGTX stock is trading below the 20-Day and 50-Day Moving averages of $0.6015 and $0.7522 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.8268.
